Meeting Banner
Abstract #3815

MRS metabolomics screening of human lung cancer with blood serum collected prior to disease diagnosis

L Cheng1, Tjada Schult1, Mara Lauer1, Yannick Berker2, Marcella Cardoso1, Lindsey Vandergrift1, Piet Habbel3, Johannes Nowak4, Martin Aryee1, Mari Mino-Kenudson1, and David Christiani5
1Mass General Hospital, Boston, MA, United States, 2German Cancer Research Center, Heidelberg, Germany, 3Charite Medical University, Berlin, Germany, 4Julius-Maximilians University, Wuerzburg, Germany, 5Harvard T.H. Chan School of Public Health, Boston, MA, United States

Lung cancer (LuCa), the leading cause of cancer deaths, are often diagnosed late due to the lack of screening. Low-dose spiral CT can detect small and early stage LuCa lesions, but cannot practically be used as an annual LuCa screening tool. Metabolomics detects global metabolite variations under physiology and pathology. Metabolomic profiles measured from blood may reveal LuCa at early stages as a screening tool to triage suspicious patients to CT tests. Blood sera obtained from LuCa patients prior to their diagnosis were studied with MRS to establish LuCa screening metabolomic profiles to discover LuCa earlier and reduce death rates.

This abstract and the presentation materials are available to members only; a login is required.

Join Here